Navigation Links
Beta Blocker Doesn't Help Children With Heart Failure
Date:9/11/2007

Trial shows no improvement with carvedilol

TUESDAY, Sept. 11 (HealthDay News) -- Carvedilol, a newer member of the beta blocker drug family that has been effective for adults with heart failure, did not help children with the condition, a new study found.

The rate of improvement -- and the lack of it -- was almost exactly the same for 103 young heart-failure patients given the drug as it was for 54 youngsters who got a placebo.

"Heart failure in children is both not common and a different kind of disease" than in adults, said Dr. Robert E. Shaddy, division chief of cardiology at Children's Hospital of Philadelphia, and lead author of the report.

Adults suffer heart failure, a progressive loss of the heart's ability to pump blood, because of coronary artery disease, Shaddy said. "Children rarely get it," he said. "In them, it is caused either by heart muscle problems or problems related to congenital malformations."

Among the 103 young people assigned to carvedilol, 56 percent improved, 19 percent were unchanged, and 24 percent worsened. Among the 54 who got conventional treatment and a placebo, 56 percent improved, 30 percent worsened, and 15 percent were unchanged.

The study findings are published in the Sept. 12 issue of the Journal of the American Medical Association.

It's still possible that the drug, which is marketed as Coreg, might help some children with heart failure, Shaddy said. An analysis of subgroups of patients in the study did show some improvement for children whose problem rested in the left ventricle, he said. "What I recommend to families based on this study is that there might possibly be a differential effect, which depends on the type of heart problem. But we were unable to prove it," he added.

Much larger studies would be needed to prove such a benefit in pediatric heart failure, and such studies would be hard to do, because the condition is rare, Shaddy said.

Dr. Samuel S. Gidding, an attending cardiologist at the Nemours Cardiac Center in Wilmington, Del., who wrote an accompanying editorial in the journal, said, "This study was underpowered [small in numbers] to show a benefit. The causes of heart failure in children are very different from the causes of heart failure in adults. Also, the drug is metabolized more quickly in children, so some patients are under-dosed, and there is a different response to drugs based on the disease class."

The study shows the hazards of extrapolating treatment results in adults to children, Gidding said. "We would need to be a lot more aggressive in trials in children to show what works and what doesn't work," he said. "We need much bigger clinical trials in kids rather than imposing conclusions from adult trials."

If further studies are to be done, Shaddy said, "we would recommend that they be done with a more homogeneous group, children with one type of heart disease."

"Children are not little adults," Gidding added. "In adulthood, there is a lot more wear and tear on the body."

More information

You can learn more about beta-blocker drugs from the Texas Heart Institute.



SOURCES: Robert E. Shaddy, M.D., chief, division of cardiology, Children's Hospital of Philadelphia; Samuel S. Gidding, M.D., attending cardiologist, Nemours Cardiac Center, Wilmington, Del.; Sept. 12, 2007, Journal of the American Medical Association


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Angiotensin-II-receptor blockers - Treat kidney failure
2. Calcium-blocker delays atherosclerosis than beta-blockers
3. Evidence against use of Beta blockers as first choice in the treatment of primary hypertension
4. Beta-Blockers Should Be the Second Line of Treatment
5. Alpha-blockers call for modification in cataract surgery
6. Beta-Blockers Should Not Be First Choice for High Blood Pressure
7. Drinking Real Juice Doesnt Cause Obesity In Children
8. Anti-smoking Ads at the Movies Doesnt Make Any Impact on Smokers
9. Fruit Juice Doesnt Cause Overweight in Kids
10. Antibiotics Dangerous for Diarrhoea in Children Caused by E.Coli
11. Inhaled Steroids Safe & Effective for Children with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... As part of their 2015 end of year ... Table Foundation (MDRTF), has gifted $10,000 to University of Chicago to support ovarian cancer ... Cundiff. , “We are honored to support a promising young investigator from Dr. Lengyel’s ...
(Date:2/10/2016)... ... February 10, 2016 , ... The ... World Molecular Imaging Congress (WMIC), will be held in New York City, NY ... “Imaging Biology…Improving Therapy.” The congress will highlight and emphasize how imaging reveals a ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Early this week, ... and raise awareness of Nestlé KITKAT as the first global confectionery brand sourced from ... cocoa farmers and the quality of their product, through activities that focus on better ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... care communications company offering education, research and medical media, has launched ... working in infectious diseases. , As the all-inclusive resource for infectious disease ...
(Date:2/10/2016)... Walton Beach, Florida (PRWEB) , ... February 10, ... ... the innovative weather-forecasting company is unveiling its revolutionary new 2.0 version at the ... platform, MetLoop has “put the power of the world's most advanced weather technology ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ... fourth quarter and full year ended December 31, 2015. ... was a transformational year for Vanda with the continued ... market approval of HETLIOZ for Non-24," said Mihael H. ... Fanapt to our U.S. product portfolio builds on this ...
(Date:2/10/2016)... , February 10, 2016 ... Analyzers (Liquid & Gas), and Spectroscopy Market by Industry (Oil ... Beverage, Pulp & Paper, Metal & Mining, and Others), ... MarketsandMarkets, the global market is expected to grow to ... of 8.6% between 2015 and 2020. Browse ...
(Date:2/10/2016)... , Feb. 10, 2016  Resolve Therapeutics, ... transformative new approaches to the treatment of lupus ... of a multiple ascending dose study in patients ... compound RSLV-132. --> ... placebo-controlled multiple ascending dose study of RSLV-132 in ...
Breaking Medicine Technology: